soul trial oral semaglutide cardiovascular outcomes 2024 2025 results shows has positive CV benefits in type 2 diabetes GLP-1 Agonists in Cardiovascular Diseases:

But the challenge of affordability, success, and clinical coordination for GLP-1 drugs in the U.S

According to Novo Nordisk, In a 68-week medical study of nearly 2000 adults living with obesity or excess weight, patients on Wegovy (along: with a reduced-calorie diet and increased physical activity) lost an average of approximately 35 pounds, with 1 in 3 adults losing as much as 45 pounds

10.1189/jlb.2RU0814-388R 14

For now, the message is clear: promising biology does not guarantee a working treatment

We classified prescriptions for Mounjaro and Ozempic (approved for T2DM) as on-label if the patient had a history of T2DM and off-label otherwise